Valuation: Atara Biotherapeutics, Inc.

Market Cap 85.12M 75.99M 69.74M 63.44M 119M 8.06B 121M 833M 336M 4.25B 319M 313M 13.43B P/E 2026 *
-8.57x
P/E 2027 * 7.15x
Enterprise Value 85.12M 75.99M 69.74M 63.44M 119M 8.06B 121M 833M 336M 4.25B 319M 313M 13.43B EV / Sales 2026 *
29.9x
EV / Sales 2027 * 2.08x
Free-Float
83.2%
Yield 2026 *
-
Yield 2027 * -
1 day+5.87%
1 week+1.56%
Current month+5.87%
1 month-10.55%
3 months+1.19%
6 months+73.06%
Current year-53.12%
1 week 7.72
Extreme 7.7231
8.84
1 month 7.72
Extreme 7.7231
9.99
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
39.5
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 09/09/2024
Director of Finance/CFO 61 26/06/2026
Investor Relations Contact - 01/07/2023
Director TitleAgeSince
Director/Board Member 62 01/03/2014
Director/Board Member 66 23/11/2015
Director/Board Member 53 09/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Buy

Director

104,166 1.0377%
17/08/26 Sell

Chief Executive Officer

-5,062 0.0562%
22/07/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
Change 5-day change 1-year change 3-year change Capi.($)
+5.87%+1.56%-42.90%-71.50% 85.12M
-2.37%-5.03%+39.49%+62.39% 62.23B
-2.87%+0.49%+11.11%+69.18% 54.92B
+0.62%+2.11%+16.96%+102.56% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
-5.47%+24.76%+101.20%+87.34% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -1.43%+4.00%+35.39%+155.78% 38.62B
Weighted average by Cap. -2.13%+2.74%+44.49%+163.81%

Financials

2026 *2027 *
Net sales 2.85M 2.54M 2.33M 2.12M 3.98M 270M 4.06M 27.88M 11.24M 142M 10.69M 10.46M 450M 40.87M 36.49M 33.48M 30.46M 57.1M 3.87B 58.24M 400M 161M 2.04B 153M 150M 6.45B
Net income -14.62M -13.05M -11.98M -10.9M -20.43M -1.38B -20.84M -143M -57.67M -731M -54.87M -53.7M -2.31B 18.66M 16.66M 15.28M 13.9M 26.07M 1.77B 26.59M 183M 73.59M 932M 70.02M 68.52M 2.94B
Net Debt - -
Projected Income Statement - Annual - Atara Biotherapeutics, Inc.
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
02/11/26 $8.480 +5.87% 32,050
30/10/26 $8.010 -6.10% 29,961
29/10/26 $8.530 -1.50% 11,873
28/10/26 $8.660 +4.34% 26,854
27/10/26 $8.300 -0.60% 21,699
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Atara Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.480USD
Average target price
13.67USD
Spread / Average Target
+61.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atara Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATRA Stock